We studied 51 sera from patients with systemic lupus erythematosus to determine the relationship of their anti-phospholipid activity to their anti-erythrocyte and complement activation properties. Forty-nine per cent of the sera had anti-phospholipid activity as demonstrated by ELISA using a panel of anionic phospholipids, and most of these also bound to neutral phospholipids, albeit to a lesser extent. A cellular radioimmunoassay was used for the detection of immunoglobulin and C3 binding to normal erythrocytes (intact, enzyme-treated or glutaraldehyde-fixed) following incubation with patient sera. The levels of IgG anti-phospholipid correlated with hypocomplementaemia and with immunoglobulin binding (paralleled by a deposition of C3 fragments) to the three types of erythrocytes, although most strongly to fixed cells. Immunoglobulin binding to intact erythrocytes correlated primarily with reactivity against neutral phospholipids. The specificity for phospholipid epitopes of immunoglobulin adsorbed onto erythrocytes was confirmed by acid elution followed by testing in ELISA. These data suggest that some anti-phospholipid antibody subsets may bind to erythrocytes in vivo, thus accounting for the observed association of these antibodies with positive direct antiglobulin tests.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1535430PMC

Publication Analysis

Top Keywords

immunoglobulin binding
12
systemic lupus
8
lupus erythematosus
8
complement activation
8
anti-phospholipid activity
8
neutral phospholipids
8
anti-phospholipid
5
erythrocytes
5
reactivity patterns
4
patterns anti-phospholipid
4

Similar Publications

Myricetin exposure reduces PC differentiation in vitro in primary human B cells.

Mol Med

January 2025

Center for Autoimmune Musculoskeletal and Hematopoietic Diseases, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell Health, 350 Community Drive, Manhasset, New York, 11030, USA.

Background: The process of B cell activation and plasma cell (PC) formation involves morphological, transcriptional, and metabolic changes in the B cell. Blocking or reducing PC differentiation is one approach to treat autoimmune diseases that are characterized by the presence of pathogenic autoantibodies. Recent studies have suggested the potential of myricetin, a natural flavonoid with anti-inflammatory and antioxidant properties, to block or reduce PC differentiation.

View Article and Find Full Text PDF

Nanobodies (Nbs) hold great potential to replace conventional antibodies in various biomedical applications. However, conventional methods for their discovery can be time-consuming and expensive. We have developed a reliable protein selection strategy that combines magnetic activated cell sorting (MACS)-based screening of yeast surface display (YSD) libraries and functional ligand-binding identification by Tat-based recognition of associating proteins (FLI-TRAP) to isolate antigen-specific Nbs from synthetic libraries.

View Article and Find Full Text PDF

Antigen receptor ITAMs provide tonic signaling by acting as guanine nucleotide exchange factors to directly activate R-RAS2.

Sci Signal

January 2025

Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 28049 Madrid, Spain.

The small GTPase R-RAS2 regulates homeostatic proliferation and survival of T and B lymphocytes and, when present in high amounts, drives the development of B cell chronic lymphocytic leukemia. In normal and leukemic lymphocytes, R-RAS2 constitutively binds to antigen receptors through their immunoreceptor tyrosine-based activation motifs (ITAMs) and promotes tonic activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Here, we examined the molecular mechanisms underlying this direct interaction and its consequences for R-RAS2 activity.

View Article and Find Full Text PDF

Rethinking Optimal Immunogens to Face SARS-CoV-2 Evolution Through Vaccination.

Influenza Other Respir Viruses

January 2025

Área de Investigación en Vacunas, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain.

SARS-CoV-2, which originated in China in late 2019, quickly fueled the global COVID-19 pandemic, profoundly impacting health and the economy worldwide. A series of vaccines, mostly based on the full SARS-CoV-2 Spike protein, were rapidly developed, showing excellent humoral and cellular responses and high efficacy against both symptomatic infection and severe disease. However, viral evolution and the waning humoral neutralizing responses strongly challenged vaccine long term effectiveness, mainly against symptomatic infection, making necessary a strategy of repeated and updated booster shots.

View Article and Find Full Text PDF

Solution-based affinity assays are used for the selection and characterization of proteins that could be developed into therapeutic molecules. However, these assays have limitations for cell-surface proteins as in most cases their purification requires detergent solubilization and are unlikely to assume conformations in solution that resemble their native states in cell membranes. This report describes a novel electrochemiluminescence-based method, called MSD-CAT, for the affinity analysis of antibodies binding to cell-surface receptors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!